Dr Sartor and dr Karmann discuss lead 212 radioligand and why dr Karmann thinks it is better than lutetium and actinium

[Maxone73]

in a nutshell, alpha emitter (more powerful than beta), shorter half life (could be synergistic with immune system and allow for more frequent dosing)…they are not talking directly about prostate cancer but I suppose prostate will be a candidate for trials!

urotoday.com/video-lectures...

[Garbonzeaux]

The good doctors dance around the "short" half life of Pb212, but never say what it is (10.64 hrs). As it turns out, the lead itself is a beta emitter, but it decays to bismuth212, which is actually the alpha emitter, with a half life of about an hour. Technical detail of no particular relevance, I guess.